Literature DB >> 31373621

HuR regulates phospholamban expression in isoproterenol-induced cardiac remodelling.

Han Hu1, Mingyang Jiang2, Yangpo Cao3, Zhuojun Zhang1, Bin Jiang1, Feng Tian4, Juan Feng3, Yali Dou5, Myriam Gorospe6, Ming Zheng3, Lemin Zheng7, Zhongzhou Yang2, Wengong Wang1.   

Abstract

AIMS: The elevated expression of phospholamban (PLB) has been observed in heart failure and cardiac remodelling, inhibiting the affinity of Ca2+ pump to Ca2+ thereby impairing heart relaxation. However, the mechanisms underlying the regulation of PLB remains to be further studied. The present study aims to test the role of RNA-binding protein HuR in the regulation of PLB and the impact of this regulatory process in cardiac remodelling. METHODS AND
RESULTS: A mouse model specifically deleted HuR in cardiomyocytes were used for testing the role of HuR in regulating PLB during isoproterenol (ISO)-induced cardiac remodelling. HuR deficiency did not significantly influence the phenotype and function of mouse heart under static status. However, deletion of HuR in cardiomyocytes mitigated the effect of ISO in inducing PLB expression and reducing β1-AR expression, in turn aggravating ISO-induced myocardial hypertrophy and cardiac fibrosis. In H9C2 cells, association of HuR with PLB and β1-AR mRNAs stabilized PLB mRNA and destabilized β1-AR mRNA, respectively.
CONCLUSION: HuR stabilizes PLB mRNA and destabilizes β1-AR mRNA. The HuR-PLB and HuR-β1-AR regulatory processes impact on ISO-induced cardiac remodelling. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Cardiac remodelling; HuR; PLB; mRNA turnover; β1-AR

Mesh:

Substances:

Year:  2020        PMID: 31373621      PMCID: PMC7868665          DOI: 10.1093/cvr/cvz205

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  41 in total

Review 1.  Molecular regulation of phospholamban function and gene expression.

Authors:  M Tada; M Yabuki; T Toyofuku
Journal:  Ann N Y Acad Sci       Date:  1998-09-16       Impact factor: 5.691

2.  Characterization of proximal transcription regulatory elements in the rat phospholamban promoter.

Authors:  C F McTiernan; B H Lemster; C S Frye; D C Johns; A M Feldman
Journal:  J Mol Cell Cardiol       Date:  1999-12       Impact factor: 5.000

Review 3.  Cardiac fibrosis: potential therapeutic targets.

Authors:  Shuin Park; Ngoc B Nguyen; Arash Pezhouman; Reza Ardehali
Journal:  Transl Res       Date:  2019-03-09       Impact factor: 7.012

Review 4.  Calcium and cardiomyopathies.

Authors:  E G Kranias; D M Bers
Journal:  Subcell Biochem       Date:  2007

5.  Structure of the rabbit phospholamban gene, cloning of the human cDNA, and assignment of the gene to human chromosome 6.

Authors:  J Fujii; A Zarain-Herzberg; H F Willard; M Tada; D H MacLennan
Journal:  J Biol Chem       Date:  1991-06-25       Impact factor: 5.157

Review 6.  Calcium pumps in health and disease.

Authors:  Marisa Brini; Ernesto Carafoli
Journal:  Physiol Rev       Date:  2009-10       Impact factor: 37.312

Review 7.  Novel signaling pathway through the beta-adrenergic receptor.

Authors:  Yong Chao Ma; Xin Yun Huang
Journal:  Trends Cardiovasc Med       Date:  2002-01       Impact factor: 6.677

8.  Increased sarcolipin expression and adrenergic drive in humans with preserved left ventricular ejection fraction and chronic isolated mitral regurgitation.

Authors:  Junying Zheng; Danielle M Yancey; Mustafa I Ahmed; Chih-Chang Wei; Pamela C Powell; Mayilvahanan Shanmugam; Himanshu Gupta; Steven G Lloyd; David C McGiffin; Chun G Schiros; Thomas S Denney; Gopal J Babu; Louis J Dell'Italia
Journal:  Circ Heart Fail       Date:  2013-12-02       Impact factor: 8.790

9.  Quantitative temporal analysis of protein dynamics in cardiac remodeling.

Authors:  Daniel B McClatchy; Yuanhui Ma; David A Liem; Dominic C M Ng; Peipei Ping; John R Yates
Journal:  J Mol Cell Cardiol       Date:  2018-07-19       Impact factor: 5.000

Review 10.  HuR function in disease.

Authors:  Subramanya Srikantan; Myriam Gorospe
Journal:  Front Biosci (Landmark Ed)       Date:  2012-01-01
View more
  7 in total

Review 1.  Non-canonical features of microRNAs: paradigms emerging from cardiovascular disease.

Authors:  Donato Santovito; Christian Weber
Journal:  Nat Rev Cardiol       Date:  2022-03-18       Impact factor: 49.421

Review 2.  The RNA-binding protein HuR in human cancer: A friend or foe?

Authors:  Xiaoqing Wu; Liang Xu
Journal:  Adv Drug Deliv Rev       Date:  2022-03-03       Impact factor: 17.873

3.  An Evolutionarily Conserved AU-Rich Element in the 3' Untranslated Region of a Transcript Misannotated as a Long Noncoding RNA Regulates RNA Stability.

Authors:  Emily A Dangelmaier; Xiao Ling Li; Corrine Corrina R Hartford; Julianna C King; Meira S Zibitt; Raj Chari; Ioannis Grammatikakis; Ashish Lal
Journal:  Mol Cell Biol       Date:  2022-03-11       Impact factor: 5.069

4.  O-ring-induced transverse aortic constriction (OTAC) is a new simple method to develop cardiac hypertrophy and heart failure in mice.

Authors:  Yasuhisa Nakao; Jun Aono; Mika Hamaguchi; Kayo Takahashi; Tomohisa Sakaue; Katsuji Inoue; Shuntaro Ikeda; Osamu Yamaguchi
Journal:  Sci Rep       Date:  2022-01-07       Impact factor: 4.379

5.  Discovery of novel 4-phenylquinazoline-based BRD4 inhibitors for cardiac fibrosis.

Authors:  Zhangxu He; Haomiao Jiao; Qi An; Xin Zhang; Dan Zengyangzong; Jiale Xu; Hongmin Liu; Liying Ma; Wen Zhao
Journal:  Acta Pharm Sin B       Date:  2021-07-24       Impact factor: 11.413

Review 6.  Circular RNAs in pulmonary hypertension: Emerging biological concepts and potential mechanism.

Authors:  Qian Wang; Yuanyuan Sun; Qinhua Zhao; Wenhui Wu; Lan Wang; Yuqing Miao; Ping Yuan
Journal:  Animal Model Exp Med       Date:  2022-01-27

7.  Puerarin attenuates isoproterenol‑induced myocardial hypertrophy via inhibition of the Wnt/β‑catenin signaling pathway.

Authors:  Xiaoying Wang; Kai He; Linlin Ma; Lan Wu; Yan Yang; Yanfei Li
Journal:  Mol Med Rep       Date:  2022-08-10       Impact factor: 3.423

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.